Pennsylvania-based Inovio Pharma announced yesterday it designed a vaccine for the novel coronavirus using its proprietary DNA-antigen technology. This is not Inovio’s first coronavirus vaccine but it places the small company in the spotlight for solutions to a potential pandemic.
Variant forms of coronaviruses have been around for at least 10,000 years. The term refers to the characteristic appearance of the virus particles (virons). However, the 2019 outbreak in Wuhan, China is designated COVID-19 has killed over one thousand three hundred (1,300) individuals.
Inovio’s Patent Holdings
Inovio holds twenty-five (25) granted United States patents focused on vaccines and related technologies. The vaccines target everything from smallpox to hepatitis C. Inovio claimed that once the Chinese government disclosed the COVID-19 DNA sequence, Inovio only needed two hours to design the vaccine and send it to manufacture using its IMMUNO-INGENUITY® branded DNA sequencing technology. Inovio expects to begin human-testing in the next few months.
Inovio has patented it’s vaccines in the past and there is little doubt it has filed pending patent applications on the COVID-19 vaccine.
|2||10,398,769||Influenza nucleic acid molecules and vaccines made therefrom|
|3||10,232,030||Vaccines for human papilloma virus and methods for using the same|
|4||10,226,526||Vaccines for human papilloma virus and methods for using the same|
|6||10,166,288||Vaccines having an antigen and interleukin-21 as an adjuvant|
|7||10,130,705||Vaccines with interleukin-33 as an adjuvant|
|8||10,124,159||Oral mucosal electroporation device and use thereof|
|9||10,087,240||DNA antibody constructs and method of using same|
|11||9,993,545||Foot and mouth disease virus (FMDV) consensus proteins, coding sequences therefor and vaccines made therefrom|
|12||9,987,347||Vaccines against multiple subtypes of dengue virus|
|13||9,913,885||Consensus prostate antigens, nucleic acid molecule encoding the same and vaccine and uses comprising the same|
|14||9,669,091||Vaccines having an antigen and interleukin-23 as an adjuvant|
|15||9,446,114||Cross-protective arenavirus vaccines and their method of use|
|16||9,446,112||Clostridium difficile DNA vaccine|
|17||9,399,056||Consensus prostate antigens, nucleic acid molecule encoding the same and vaccine and uses comprising the same|
|18||9,156,891||Vaccines and methods for using the same|
|19||9,156,890||HCV vaccines and methods for using the same|
|20||9,109,014||Foot and mouth disease virus (FMDV) consensus proteins, coding sequences therefor and vaccines made therefrom|
|21||9,034,313||Nucleic acid molecules encoding rantes, and compositions comprising and methods of using the same|
|22||8,927,692||Consensus prostate antigens, nucleic acid molecule encoding the same and vaccine and uses comprising the same|
|23||8,921,536||HCV vaccines and methods for using the same|
|24||8,829,174||HCV vaccines and methods for using the same|
|25||8,535,687||Smallpox DNA vaccine and the antigens therein that elicit an immune response|
Inovio was likely jump-started from funding from a U.S. Department of Defense grant to the University of Pennsylvania (U. Penn) for a smallpox vaccine over a decade ago. U. Penn continues to be a stakeholder in Inovio’s patent portfolio including its most recent February 4, 2020, U.S. Patent 10,548,971 for a MERS-CoV coronavirus vaccine.